Success examples
Functional characterization of pathway inhibitors for the ubiquitin-proteasome system (UPS) as tool compounds for CRBN and VHL-mediated targeted protein degradation

Schwalm M. P., Menge A., Elson L., Greco F. A., Robers M. B., Müller S., Knapp S.

ACS Chem Biol. 2025, 20(1):94-104.

BET PROTAC
DOI
PubMed
Success examples
Sex Matters–Insights from Testing Drug Efficacy in an Animal Model of Pancreatic Cancer

Schulz B., Leitner E., Schreiber T., Lindner T., Schwarz R., Aboutara N., Ma Y., Ecobar H. M., Palme R., Hinz B., Vollmar B., Zechner D.

Cancers (Basel). 2024, 16(10):1901.

SOS1::KRAS inhibitor
DOI
PubMed
Success examples
Pharmacological inhibition of cathepsin S and of NSPs-AAP-1 (a novel, alternative protease driving the activation of neutrophil serine proteases)

Domain R., Seren S., Jerke U., Makridakis M., Chen KJ., Zoidakis J., Rhimi M,, Zhang X., Bonvent T., Croix C., Gonzalez L., Li D., Basso J., Paget C., Viaud-Massuard MC., Lalmanach G., Shi GP., Aghdassi A., Vlahou A., McDonald PP., Korkmaz B.

Biochemical Pharmacology 2024, 229:116114.

Cathepsin C inhibitor
DOI
PubMed
Success examples
Aurora B kinase inhibition intensifies cisplatin cytotoxicity in MCF7 breast cancer cells

Askan R., Gundogdu R.

EJM. 2024, 63(3):410-21.

Aurora B inhibitor
DOI
Success examples
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade

Nokin M-J., Mira A., Patrucco E., Ricciuti B., Cousin S., Soubeyran I., San José S., Peirone S., Caizzi L., Vietti Michelina S., Bourdon A., Wang X., Alvarez-Villanueva D., Martínez-Iniesta M., Vidal A., Rodrigues T., García-Macías C., Awad M. M., Nadal E., Villanueva A., Italiano A., Cereda M., Santamaría D., Ambrogio C.

Nat Commun 2024, 15(1):7554.

SOS1::KRAS inhibitor
DOI
PubMed